Elite Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Elite Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Elite Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Elite Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Elite Pharmaceuticals Inc (Elite) is a speciality pharmaceutical company that focuses on the development of oral sustained and controlled release drug products. The company manufactures and develops generic drugs upon marketing approvals via Abbreviated New Drug Applications (ANDA) and branded drugs via New Drug Application (NDA) for the treatment of cardiovascular disorders, allergies, infections, bariatric and other conditions. Its key commercialized product portfolio includes Adipex-P, Bontril for Bariatric therapy; Revia for Pain related; Dantrium for muscle relaxation; Adderall XR for the central nervous system; Loxapine for Antipsychotic, among others. Elite also has a pipeline of abuse-deterrent opioids for the treatment of chronic pain. The company uses its proprietary ART (abuse-deterrent technology) platform to develop and manufacture oral, controlled-release drugs. Elite is headquartered in Northvale, New Jersey, the US.
Headquarters
United States of America
Address
165 Ludlow Avenue, Northvale, New Jersey, 07647
Website
www.elitepharma.com
Telephone
1 201 7502646
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ELTP (OTC)
Revenue (2025)
$84.0M
48.4%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-121.5%
(2025 vs 2024)
Market Cap*
$395.0M
Net Profit Margin (2025)
XYZ
-114.5%
(2025 vs 2024)
* As of and is in US$
Elite Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic | SequestOx |
| Pain: | Adipex-P |
| Acetaminophen and Codeine Phosphate | Revia |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Regulatory Approval | In April, the company received approval from the US Food and Drug Administration (FDA) for doxycycline hyclate 100 mg tablets. Doxycycline hyclate is an antibiotic that is used to treat a wide variety of bacterial infections. |
| 2021 | Contracts/Agreements | In May, the company entered into a license, supply, and distribution agreement with Prasco for Elite for Loxapine Succinate capsules, 5 mg, 10 mg, 25 mg, and 50 mg. |
| 2020 | New Products/Services | In March, the company launched a generic version of Adderall XR with its marketing partner Lannett Company Inc. |
Competitor Comparison
| Key Parameters | Elite Pharmaceuticals Inc | Sandoz Inc | Collegium Pharmaceutical Inc | Acura Pharmaceuticals Inc | Aurobindo Pharma USA Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Northvale | Princeton | Stoughton | Palatine | East Windsor |
| State/Province | New Jersey | New Jersey | Massachusetts | Illinois | New Jersey |
| No. of Employees | 68 | - | 357 | - | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carter Ward | Chief Financial Officer | Senior Management | 2023 | 61 |
| Kirko Kirkov | Chief Commercial Officer | Senior Management | 2022 | 57 |
| George Kenneth Smith | Vice President - Legal | Senior Management | 2014 | - |
| Douglas Plassche | Executive Vice President - Operations | Senior Management | 2013 | 61 |
| Chris Dick | Head - Development | Senior Management | 2013 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer